Ryan Isom, MD
Retina Specialist · Provo, UTNPI 1679756019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 79.8% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $151, 5.6 times the $27 reported in 2019. That places this record below the midpoint for retina specialist clinicians in UT, where the typical reported total is $2,710.
Across 19 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$322
- Regeneron Healthcare Solutions, Inc.$39
- Apellis Pharmaceuticals, Inc.$29
- Novartis$14
What the payments were for
- Food & beverage$403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $322 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Novartis | 1 | $14 |
How this compares
$403 in reported general payments places this provider in the 15th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 64 | $2,758 |
| Difluprednate | 14 | $2,593 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 155 | $1,791 |
| Travoprost | 12 | $1,655 |
| Latanoprost | 106 | $1,485 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $684 |
| Timolol Maleate | 57 | $578 |
| Brimonidine Tartrate | 19 | $145 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $102 |
| Acyclovir | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Provo
- Robert WelchProvo$840
- Jonathan GuntherProvo$632
- Jack StringhamProvo$331
- Richard CoreyProvo$147
- Robert KwunSalt Lake City$334K
- Mitchell GoffSalt Lake City$165K
- James HowardSalt Lake City$14K
- David FaberSalt Lake City$10K
- Rebekah GensureSalt Lake City$5K
- Andrew DavisWest Jordan$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.